Changes in bone marrow and urinary manifestations of angiogenesis and myelofibrosis in 10 patients with MMM completing 6 months of THAL-PRED therapy
| Patient no. . | Responses . | Cellularity, % . | RF . | Osteosclerosis . | Angiogenesis . | Karyotype . | Urinary VEGF . | Urinary bFGF . | Urinary TSP . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hb . | PLT . | Spleen . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | |
| 2 | Y | NA | N | 95 | 90 | 1.5 | 1.5 | 0 | 0 | 4 | 4 | 18p+ | 18+ | NA | 224.33 | NA | 2650 | NA | 32 087 |
| 3 | Y | NA | Y | 70 | 80 | 2.0 | 2 | 0 | 0 | 4 | 4 | Normal | Normal | 82.44 | 75.72 | 2121 | 5906 | 37 802 | 44 194 |
| 4 | Y | NA | N | 80 | 80 | 2.5 | 2.5 | 0 | 0 | 3 | 3 | Normal | Normal | 63.74 | 15.49 | 2039 | 1609 | 46 902 | 33 135 |
| 5 | Y | Y | Y | 5 | 5 | 3.0 | 3 | 0 | 0 | 3 | 2 | t(1;10) | NA | 58.94 | 89.18 | 4037 | 4520 | 56 000 | 57 213 |
| 7 | Y | NA | N | 50 | 70 | 2.0 | 1.5 | 0 | 0 | 4 | 3 | Normal | Normal | 21.04 | 12.18 | 1647 | 2988 | 27 299 | 32 246 |
| 11 | Y | NA | Y | 30 | 35 | 2.0 | 1.5 | 2 | 2 | 3 | 3 | 20q− | 20q− | 32.90 | 60.43 | 2972 | 4030 | 63 200 | 70 189 |
| 12 | Y | Y | N | 40 | 40 | 1.5 | 1 | 0 | 0 | 4 | 4 | Normal | Normal | 55.77 | 28.83 | 5062 | 2359 | 58 519 | 35 742 |
| 13 | Y | Y | N | 40 | 55 | 2.0 | 2 | 0 | 0 | 4 | 4 | 20q− | 20q− | 190.16 | 155.97 | 2430 | 3264 | 53 153 | 54 597 |
| 14 | Y | NA | Y | 30 | 50 | 1.5 | 2.5 | 3 | 2.5 | 3 | 4 | Normal | Normal | 132.89 | 37.78 | 1118 | 939 | 35 862 | 13 944 |
| 21 | Y | Y | N | 5 | 10 | 2.0 | 2 | 0 | 0 | 2 | 1 | Normal | Normal | 26.88 | 68.52 | 4606 | 3692 | 49 375 | 66 872 |
| Patient no. . | Responses . | Cellularity, % . | RF . | Osteosclerosis . | Angiogenesis . | Karyotype . | Urinary VEGF . | Urinary bFGF . | Urinary TSP . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hb . | PLT . | Spleen . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | Time 0 . | 6 mo . | |
| 2 | Y | NA | N | 95 | 90 | 1.5 | 1.5 | 0 | 0 | 4 | 4 | 18p+ | 18+ | NA | 224.33 | NA | 2650 | NA | 32 087 |
| 3 | Y | NA | Y | 70 | 80 | 2.0 | 2 | 0 | 0 | 4 | 4 | Normal | Normal | 82.44 | 75.72 | 2121 | 5906 | 37 802 | 44 194 |
| 4 | Y | NA | N | 80 | 80 | 2.5 | 2.5 | 0 | 0 | 3 | 3 | Normal | Normal | 63.74 | 15.49 | 2039 | 1609 | 46 902 | 33 135 |
| 5 | Y | Y | Y | 5 | 5 | 3.0 | 3 | 0 | 0 | 3 | 2 | t(1;10) | NA | 58.94 | 89.18 | 4037 | 4520 | 56 000 | 57 213 |
| 7 | Y | NA | N | 50 | 70 | 2.0 | 1.5 | 0 | 0 | 4 | 3 | Normal | Normal | 21.04 | 12.18 | 1647 | 2988 | 27 299 | 32 246 |
| 11 | Y | NA | Y | 30 | 35 | 2.0 | 1.5 | 2 | 2 | 3 | 3 | 20q− | 20q− | 32.90 | 60.43 | 2972 | 4030 | 63 200 | 70 189 |
| 12 | Y | Y | N | 40 | 40 | 1.5 | 1 | 0 | 0 | 4 | 4 | Normal | Normal | 55.77 | 28.83 | 5062 | 2359 | 58 519 | 35 742 |
| 13 | Y | Y | N | 40 | 55 | 2.0 | 2 | 0 | 0 | 4 | 4 | 20q− | 20q− | 190.16 | 155.97 | 2430 | 3264 | 53 153 | 54 597 |
| 14 | Y | NA | Y | 30 | 50 | 1.5 | 2.5 | 3 | 2.5 | 3 | 4 | Normal | Normal | 132.89 | 37.78 | 1118 | 939 | 35 862 | 13 944 |
| 21 | Y | Y | N | 5 | 10 | 2.0 | 2 | 0 | 0 | 2 | 1 | Normal | Normal | 26.88 | 68.52 | 4606 | 3692 | 49 375 | 66 872 |
Urinary angiogenesis markers were done by ELISA and corrected for urinary creatinine. VEGF values in are in ng/g creatinine; normal value is 140 ng/g creatinine. bFGF values are in pg/g creatinine; normal value is 11 512 pg/g creatinine. TSP values are in ng/g creatinine; normal value is 57 732 pg/g creatinine. Hb indicates hemoglobin response; PLT, platelet count response; Spleen, spleen response; RF, reticulin fibrosis grade 0-4; Karyotype, G-banded karyotype on 20 metaphases from bone marrow aspirate at time of registration; N, no; NA, not available; Y, yes.